Dyadic International (DYAI) EBITDA Margin (2018 - 2026)
Dyadic International (DYAI) posted EBITDA Margin of 171.27% for Q1 2026, down 279.29% sequentially from 95.52% in Q4 2025, and up 33753.0% YoY from N/an in Q1 2025.
Dyadic International (DYAI) EBITDA Margin (2018 - 2026) Analysis & Trends
Dyadic International has reported EBITDA Margin for 9 years, with the latest figure at 171.27% in Q1 2026.
- Quarterly EBITDA Margin rose 33753.0% year-over-year to 171.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 434.0% (down 27145.0% YoY) and the FY2025 annual result came in at 784.43%, down 61561.0% from the prior year.
- EBITDA Margin declined to 171.27% in Q1 2026 per DYAI's latest filing, from 95.52% in the prior quarter.
- Over five years, EBITDA Margin peaked at 95.52% in Q4 2025 and troughed at 635.22% in Q1 2024.
- A 5-year average of 291.96% and a median of 273.6% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin soared 104452 bps in 2022, then sank 42557 bps in 2024.
- Over 5 years, EBITDA Margin stood at 301.13% in 2022, then dropped by 5 bps to 315.89% in 2023, then soared by 41 bps to 187.19% in 2024, then soared by 151 bps to 95.52% in 2025, then tumbled by 279 bps to 171.27% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 171.27%, 95.52%, and 165.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | -171.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -171.27% |
| Dec 31, 2025 | 95.52% |
| Sep 30, 2025 | -165.32% |
| Jun 30, 2025 | -178.88% |
| Mar 31, 2025 | -508.80% |
| Dec 31, 2024 | -187.19% |
| Sep 30, 2024 | -10.35% |
| Jun 30, 2024 | -529.31% |
| Mar 31, 2024 | -635.22% |
| Dec 31, 2023 | -315.89% |
| Sep 30, 2023 | -433.21% |
| Jun 30, 2023 | -273.60% |
| Mar 31, 2023 | -209.65% |
| Dec 31, 2022 | -301.13% |
| Sep 30, 2022 | -211.86% |
| Jun 30, 2022 | -503.83% |
| Mar 31, 2022 | -423.28% |
| Dec 31, 2021 | -1,345.65% |
| Sep 30, 2021 | -479.70% |
| Jun 30, 2021 | -412.67% |